Kymera Investor Presentation Deck

Mean (± SE) Percent IRAK4 Change from Baseline 50 -20 -40 -60 -80 -100 ● ● KT-474 Healthy Volunteer Study: Robust and Sustained IRAK4 Degradation Leading to Broad Cytokine Impact 1 2 3 4 Mean % Reduction of IRAK4 (Daily oral doses for 14 days) 7 Dosing period 14 Day 17 21 KYMERA ©2023 KYMERA THERAPEUTICS, INC. Placebo 25 mg QD 50 mg QD 100 mg QD 200 mg QD Detected by mass spectrometry in circulating PBMC Steady state IRAK4 reduction achieved between Days 7 and 14 Recovery towards baseline by Day 28 (2 weeks after last dose) 50-200 mgs approached Lower Limit of Quantitation (LLOQ) 28 Ex Vivo Inhibition of 9 Disease-Relevant Cytokines, Day 7-14 R848 (TLR7/8) Stimulation Placebo (n = 9) 50 mg QD (n = 9) 100 mg QD (n = 8-9*) Pbo 50 mg QD 200 100 -50 -100 IFNY IL10 IL6 >500% -62% 15% -85% -59% 35% -18% IL8 IL10 IL12 -53% -5% -28% -23% 100 mg -68% QD Mean values > 200% have been replaced by 200 for visualization purposes *n=8 for LPS, n=9 for R848 2% -32% -50% 3% -58% -72% IL17 107% -24% -46% IRAK4 MAD TNFa -7% -21% -59% PAGE 11

View entire presentation